FDA Issues Complete Response Letter for Cytisinicline, Citing Manufacturing Deficiencies

Achieve Life Sciences' NDA 217082 receives a CRL on manufacturing grounds after two Phase 3 trials (ORCA-2, ORCA-3; combined n=1,602) demonstrated efficacy — leaving clinical data intact but approval contingent on GMP remediation.

Biotech Business Desk Saturday, 20 June 2026 · 2 min read

The FDA issued a Complete Response Letter (CRL) for cytisinicline (NDA 217082) on June 19, 2026, declining to approve the plant-derived smoking cessation compound pending resolution of manufacturing deficiencies identified during the agency’s pre-approval inspection of the drug substance facility. The clinical data package was not cited as a deficiency.

Cytisinicline is an alkaloid derived from the seeds of Laburnum anagyroides, where it occurs naturally as a partial agonist at α4β2 nicotinic acetylcholine receptors — the same receptor subtype targeted by varenicline (Chantix/Champix). The compound has been used as an over-the-counter smoking cessation aid in several Eastern European countries for decades under the name Tabex, but NDA 217082 represents the first application for FDA approval of a cytisinicline product in the United States.

The clinical efficacy package includes two Phase 3 trials conducted by Achieve Life Sciences: ORCA-2 (810 participants) and ORCA-3 (792 participants), for a combined randomized enrollment of 1,602 patients. Both trials demonstrated statistically significant improvements in continuous abstinence rates versus placebo, and the safety profile showed a tolerability advantage over the nausea burden associated with varenicline at standard doses.

Approximately 48 million Americans use tobacco products, according to the CDC’s 2024 National Health Interview Survey data. Existing pharmacotherapy — including varenicline, bupropion, and nicotine replacement therapy — leaves a meaningful proportion of smokers without adequate cessation support. Cytisinicline’s lower cost of goods relative to varenicline has been cited by advocates as a potential access advantage for lower-income populations.

Manufacturing-related CRLs are common in complex natural-product drug applications, where standardizing extraction, purification, and quality control to GMP requirements can require facility upgrades or supply-chain changes. Achieve Life Sciences has stated its intention to respond to the CRL by addressing the manufacturing observations and resubmitting. No resubmission timeline has been disclosed. The clinical program appears intact.

FDA CRL, NDA 217082, cytisinicline, June 19, 2026. ORCA-2 and ORCA-3 trials, Achieve Life Sciences. CDC National Health Interview Survey, 2024.

Trace · every claim, sourced

Reported and written by Biotech Business Desk, then each load-bearing claim was bound to the primary source it rests on and checked out-of-band against that source before publication. The full mapping is below — nothing here is taken on faith.

The FDA issued a CRL for cytisinicline NDA 217082 on June 19, 2026, citing manufacturing deficiencies; clinical efficacy and safety data were not cited as deficiencies.

source on file

The NDA includes two Phase 3 trials — ORCA-2 (810 participants) and ORCA-3 (792 participants), combined n=1,602 — both demonstrating significant continuous abstinence improvement over placebo.

source on file

Approximately 48 million Americans use tobacco products, per CDC National Health Interview Survey 2024 data.

source on file

After publication, a separate AI panel re-verifies every edition against these same sources. The running claim-confirmation rate and every correction are public on the accuracy ledger.